Asterias Biotherapeutics, Inc. (AST): Edward Wirth , Chief Medical Officer of Asterias Biotherapeutics, Inc. sold 14,760 shares on Sep 8, 2016. The Insider selling transaction was reported by the company on Sep 12, 2016 to the Securities and Exchange Commission. The shares were sold at $3.54 per share for a total value of $51,917.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 12, 2016, Katharine E. Spink (Chief Operating Officer) sold 19,336 shares at $3.52 per share price.On Jul 1, 2016, Richard T. Lebuhn (director) purchased 5,000 shares at $2.38 per share price.Also, On Jul 1, 2016, Stephen Lahue Cartt (CEO) purchased 10,000 shares at $2.40 per share price.On Jun 10, 2016, Alfred D Kingsley (director) purchased 4,000 shares at $2.93 per share price.
Asterias Biotherapeutics Inc: On Monday, Sep 12, 2016 heightened volatility was witnessed in Asterias Biotherapeutics Inc which led to swings in the share price. The shares opened for trading at $4 and hit $4.01 on the upside , eventually ending the session at $3.93, with a gain of 1.29% or 0.05 points. The heightened volatility saw the trading volume jump to 587,270 shares. The 52-week high of the share price is $6.4 and the company has a market cap of $178 M . The 52-week low of the share price is at $2.3.
Asterias Biotherapeutics Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company’s product development is focused primarily on AST-OPC1 and AST-VAC2. The Company’s lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).